VT
CORT icon

Vise Technologies’s Corcept Therapeutics CORT Stock Holding History

Vise Technologies’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$814K Buy
9,366
+1,519
+19% +$91.7K 0.01% 900
2026
Q1 		$273K Hold
7,847
– – 0.01% 1193
2025
Q4 		$273K Buy
7,847
+4,515
+136% +$355K 0.01% 1201
2025
Q3 		$277K Sell
3,332
-362
-10% -$26.2K 0.01% 940
2025
Q2 		$271K Buy
+3,694
New +$268K 0.01% 878
2024
Q4 		$204K Buy
+4,046
New +$212K 0.02% 771

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vise Technologies's CORT Position: Q2 2026 in Review

Vise Technologies increased its Corcept Therapeutics (CORT) stake by 19% in Q2 2026, buying an estimated $91.7K and bringing the position to 9,366 shares worth $814K. The position accounts for 0.01% of the portfolio, ranked #900.

Vise Technologies first reported a position in CORT in Q4 2024 and has held it in 6 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Vise Technologies held 9,366 shares of Corcept Therapeutics worth $814K as of Q2 2026.
  • Vise Technologies bought 1,519 Corcept Therapeutics shares in Q2 2026, an estimated $91.7K.
  • Corcept Therapeutics made up 0.01% of Vise Technologies's portfolio in Q2 2026, its #900 holding.
  • Vise Technologies first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Vise Technologies's 13F filing for Q2 2026, filed 11 Aug 2026.